Overview of the renin-angiotensin system

Korean Circulation Journal

Volumn 37, Issue 3, 2007, Pages 91-96

  Wang, Seong Ryu ^a   Sang, Wook Kim ^a   Chee, Jeong Kim ^a  

^a Chung Ang University College of Medicine   (South Korea)

Author keywords

Angiotensin II; Angiotensin II receptor; Angiotensin converting enzyme 2; Angiotensin converting enzyme inhibitors; Renin

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE; ENALAPRIL; EPROSARTAN; FOSINOPRIL; GUANINE NUCLEOTIDE BINDING PROTEIN; IRBESARTAN; LISINOPRIL; LOSARTAN; OCTAPEPTIDE; OLMESARTAN; RAC PROTEIN; RAMIPRIL; RAS PROTEIN; RENIN; RHO FACTOR; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

BLOOD PRESSURE; BLOOD VESSEL TONE; CELL MIGRATION; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FLUID BALANCE; HEART HYPERTROPHY; HEART INFARCTION; HEART VENTRICLE REMODELING; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM BALANCE; SURVIVAL; VASCULAR SMOOTH MUSCLE;

EID: 34247248806     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2007.37.3.91     Document Type: Review

References (51)

1. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-91.
2. Ohtsu H, Suzuki H, Nakashima H, et al. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 2006; 48:534-40.
3. Kim KB. The role of angiotensin receptor antagonist in patients with hypertension and cardiovascular diseases. Korean Circ J 1999;29:335-40.
4. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005;23:S9-17.
5. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24:11-25.
6. Weber MA. Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens Suppl 2006;24:S37-44.
7. Sokol SI, Portnay EL, Curtis JP, et al. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004;63:208-13.
8. Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003;21-1599-608.
9. Jeon ES. Role of angiotensin II receptor blockers in the treatment of congestive heart failure. Korean Circ J 2002;32:1039-45.
10. Mancia G. Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 2006;24-S17-24.
11. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006;98:463-71.
12. Farmer JA. Renin angiotensin system and ASCVD. Curr Opin Cardiol 2000;15:141-50.
13. Ulfendahl HR, Aurell M. Renin-Angiotensin: a centenary symposium of the discovery of the renin-angiotensin system. London: Portland Press: 1998. p. 1-12.
14. Suh SY, Park CG, Chwe UR, et al. Plasma renin activity and clinical implication in Korean hypertensive patients. Korean Circ J 2005;35:658-64.
15. Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE, Berk BC. Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc Res 1995;30:511-7.
16. Pan L, Gross KW. Transcriptional regulation of renin. Hypertension 2005;45:3-8.
17. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996;28-803-12.
18. Beierwaltes WH. Renin synthesis and secretion. In: Izzo JL, Black HR, editor. Hypertension Primer. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 14-7.
19. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens 2007;25:25-35.
20. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997;80: 607-16.
21. de Leeuw PW. How do angiotensin II receptor antagonists affect blood pressure? Am J Cardiol 1999;84:5K-6K.
22. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005;97: 434-42.
23. 2. Hypertension 2005;46:732-7.
24. 1 receptor signaling in vascular smooth muscle. Circ Res 2005;97:829-36.
25. Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668-76.
26. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Phamacol 2002; 39:319-27.
27. Calo LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone: evidence from studies in humans. J Hypertens 2007;25:259-64.
28. Smith NJ, Luttrell LM. Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease. Hypertension 2006;48:173-9.
29. Yang CH, Lee SH, Park TH, et al. Gene expression profile of volume-overloaded human ventricular myocardium prior to developing heart failure. Korean Circ J 2005;35:649-57.
30. Fleming I. Signaling by the angiotensin-converting enzvme. Circ Res 2006;98:887-96.
31. 1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999;20:997-1008.
32. Hollenberg NK. Hypertension, small arteries, and pathways for angiotensin II generation. Circulation 2000;101:1641-2.
33. Linger T, Culman J, Peter G. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998;16:S3-9.
34. Diez J. Profibrotic effects of angiotensin II in the heart. Hypertension 2004;43:1164-5.
35. Wolf G, Wenzel UO. Angiotensin II and cell cycle regulation. Hypertension 2004;43:693-8.
36. Kim YH, Son JH, Piao H, et al. Role of angiotensin II type 1A receptor-mediated signaling in the development of pressure overload-induced left ventricular hypertrophy and fibrosis. Korean Circ J 2006;36:626-34.
37. Kim KM, Kim IS, Park SJ, et al. Effects of angiotensin II on the growth of vascular smooth muscle cells. Korean Circ J 1999;29: 209-15.
38. Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikreinkinin systems. Hypertension 2005;46:1236-42.
39. Sampaio WO, Souza dos Santos RA, Faria-Silva R, de Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin- (1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-depcndent pathways. Hypertension 2007;49:185-92.
40. Brown NJ, Vaughan DE. Angiotensin-converting enzvme inhibitors. Circulation 1998;97:1411-20.
41. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006;98:1123-33.
42. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006;113:2851-60.
43. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998;16:S23-9.
44. Alfakin K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006; 24:1223-30.
45. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005;23:S27-33.
46. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
47. Rigat B, Hubert C, Corvol P. Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DCPI) (dipeptidyl carboxypeptidase I). Nucleic Acids Res 1992;20:1433.
48. Rosendorff C. Vascular hypertrophy in hypertension: role of the renin-angiotensin system. Mt Sinai J Med 1998;65:108-17.
49. Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens 2001;10:617-24.
50. Schulman IH, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. Hypertension 2007;49:270-1.
51. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.